Business Context and Reporting Period
Company: International Flavors & Fragrances Inc. (IFF)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: IFF is a global leader in flavors, fragrances, and functional ingredients. The company operates through four reportable segments: Taste, Food Ingredients, Health & Biosciences, and Scent. The Pharma Solutions segment was divested in May 2025.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $2,741 | $2,843 |
| Gross Profit | $1,018 | $1,035 |
| Gross Margin | 37.1% | 36.4% |
| Operating Profit | $273 | $(903) |
| Operating Margin | 10.0% | (31.8)% |
| Net Income (Attributable to IFF) | $169 | $(1,018) |
| Diluted EPS | $0.66 | $(3.98) |
| Adjusted Operating EBITDA | $568 | $578 |
| Operating Cash Flow | $257 | $127 |
| Cash and Cash Equivalents | $562 | $650 |
| Total Debt | $5,817 | $5,994 |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability with $169 million in net income, a significant improvement from the $1.018 billion net loss in Q1 2025. The prior year loss was heavily impacted by a $1.153 billion goodwill impairment charge related to the Food Ingredients reporting unit, which did not recur in 2026.
- Revenue Trends: Reported net sales decreased 4% to $2.741 billion, primarily due to the exclusion of divested businesses (Pharma Solutions, Nitrocellulose, and Soy Crush/Concentrates/Lecithin). On a comparable currency-neutral basis, sales increased 3%.
- Divestitures: IFF completed the divestiture of the Soy Crush, Concentrates, and Lecithin (SCL) business on March 2, 2026, recognizing a pre-tax loss of $7 million and receiving $105 million in cash proceeds.
- Expense Management: Selling and administrative expenses decreased 7% to $427 million, driven by lower consulting fees related to divestitures. Restructuring charges dropped to $6 million from $17 million in the prior year.
- Segment Performance: Health & Biosciences led growth with a 10% reported sales increase. All remaining segments (Taste, Food Ingredients, Scent) showed reported sales growth of 5-6%.
Guidance, Outlook, and Risks
- Capital Allocation: The company continues its share repurchase program (authorized $500 million in August 2025), repurchasing approximately $35 million of stock in Q1 2026. A quarterly dividend of $0.40 per share was declared.
- Capital Expenditures: Management expects 2026 capital spending to be approximately 6% of sales, an increase from 5.5% in 2025, reflecting re-prioritized projects.
- Liquidity: The company maintains a $2 billion Revolving Credit Facility with no outstanding borrowings as of March 31, 2026. The net debt to credit-adjusted EBITDA ratio was 2.53x, well within the 3.75x covenant limit.
- Legal and Regulatory Risks:
- Antitrust Investigations: Ongoing investigations into potential anticompetitive conduct in the fragrance business by the EU, UK, and other jurisdictions. The U.S. DOJ investigation was closed in February 2026. IFF has settled U.S. direct purchaser class actions ($26 million contribution) and is negotiating indirect purchaser settlements.
- Frutarom Litigation: A securities class action in Israel regarding the Frutarom acquisition was settled in November 2025, with costs covered by insurers.
- Tariff Refunds: Following a Supreme Court ruling invalidating certain IEEPA-based tariffs, IFF has not yet recognized assets for potential refunds due to uncertainty regarding the approval process and potential pass-through obligations to customers.
Investor Verification Checklist
- Divestiture Impact: Verify the final net proceeds and post-closing adjustments for the SCL divestiture completed in March 2026.
- Antitrust Exposure: Monitor the status of ongoing antitrust investigations in the EU, UK, and other jurisdictions, and the finalization of indirect purchaser class action settlements.
- Tariff Refund Realization: Track the progress of U.S. Customs and Border Protection (CBP) refund requests and the likelihood of retaining any refunded amounts versus passing them to customers.
- Goodwill Impairment Risk: Assess the sensitivity of the Taste reporting unit to changes in revenue growth and discount rates, as noted in management's discussion of impairment testing.
- Productivity Program Execution: Review the progress of the IFF Productivity Program, which aims to save $110-$130 million, to ensure cost targets are met without impacting operational capacity.